Literature DB >> 621817

Adjuvant chemotherapy for bladder cancer with doxorubicin hydrochloride and cyclophosphamide: preliminary report.

C Merrin, S Beckley.   

Abstract

We describe 25 patients with bladder cancer who received adjuvant chemotherapy with doxorubicin hydrochloride and cyclophosphamide after radical cystectomy. Two patients had stage A disease, 3 had stage B, 3 had stage C and 17 had stage D. The 2 patients with stage A tumors have been free of disease for 12 and 15 months, respectively, and the 3 patients with stage B tumors have been free of disease for an average of 25 months. Of the 3 patients with stage C tumors 2 have been free of disease for an average of 34.5 months. Of the 17 patients with stage D tumors 10 have been free of disease for an average of 1 year (59 per cent). These preliminary results seem to indicate the value of adjuvant chemotherapy with doxorubicin hydrochloride and cyclophosphamide in cases of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 621817     DOI: 10.1016/s0022-5347(17)57384-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Adjuvant chemotherapy for invasive bladder cancer.

Authors:  Y Uekado; T Shinka; A Hirano; T Ohkawa
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 2.  Adjuvant chemotherapy following radical cystectomy.

Authors:  C N Sternberg
Journal:  World J Urol       Date:  1993       Impact factor: 4.226

3.  Results of systemic chemotherapy of advanced bladder carcinomas (phase II study).

Authors:  G Stadie; A Möller; H Müller; D Katenkamp; H Urban; D Kob
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

4.  Postoperative systemic adjuvant chemotherapy for bladder cancer.

Authors:  H Kiyohara; M Kuroda; S Saiki; T Miki; T Kinouchi; M Usami; T Kotake
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Adjuvant chemotherapy for non-organ confined disease after radical cystectomy.

Authors:  A Tekin; H Ozen
Journal:  Int Urol Nephrol       Date:  2000       Impact factor: 2.266

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.